TFFD-rVSV-SARS2-GP

TFFD-rVSV-SARS2-GP is a **dry powder recombinant vaccine** against COVID-19 formulated using Thin Film Freezing (TFF) technology. It utilizes the recombinant vesicular stomatitis virus (rVSV) platform engineered to express the glycoprotein (spike protein) of SARS-CoV-2. The vaccine is designed for intranasal or pulmonary administration and aims for enhanced stability, broad protection, and needle-free delivery. The mechanism of action is based on viral vector-mediated antigen presentation—eliciting immune responses against the SARS-CoV-2 spike glycoprotein. The vaccine is being evaluated as a rapid, temperature-stable countermeasure to COVID-19 and possibly other respiratory viruses. Preclinical studies assess immunogenicity, protection, and administration routes including intranasal and intramuscular. The current primary indication is prevention of COVID-19[1][3][5][7].

Brand names

TFFD-rVSV-SARS2-GPTFFD-rVSV-SARS-2-GPTFFD-rVSV-SARS 2-GP

Other names

TFFD-rVSV-SARS2-GPTFFD-rVSV-SARS-2-GPTFFD-rVSV-SARS 2-GPdry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein vaccine